The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
CTEPH is one of the leading causes of severe pulmonary hypertension (PH), classified within World Health Organization (WHO) group 4 PH. It is a rare, progressive pulmonary vascular disease that if left untreated, leads to progressively increasing pulmonary vascular resistance (PVR) and eventually right ventricle failure and death. Histopathologic findings including endothelial cell dysfunction and distal pulmonary arterial remodeling are shared between PAH and CTEPH, and PH-specific therapies (that is, riociguat) have shown efficacy in inoperable and persistent/recurrent CTEPH. The endothelin receptor antagonist macitentan offers a different mode of action and addresses an important unmet medical need for an alternative treatment option in this indication. This study will assess the effect of macitentan 75 mg on exercise capacity and is expected to confirm the role of macitentan as a first line, as well as add-on treatment for CTEPH. The study comprises of screening period (at least 14- and up to 60 days), a 52-week double-blind (DB) treatment period (which includes an 8-week up-titration phase), an open-label (OL) extension period (which starts at Week 52 and will end for all participants 104 weeks after the last participant has completed the DB treatment period) and 30-day safety follow-up period. Participants who discontinue DB study intervention will be followed until Week 52 in a post-treatment-observation period (PTOP). The total duration of the study is approximately 6 years.
|Clinical Study Identifier||NCT04271475|
|Last Modified on||4 December 2020|
Select a piece of text and start making personal notes.
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.Learn more
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.Learn more
Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.Learn more
Congrats! You have your own personal workspace now.